Viii Lp Canaan Partners Vii... Net Worth

The estimated Net Worth of Viii Lp Canaan Partners Vii... is at least $39.3 million dollars as of 26 July 2021. Viii Vii owns over 11,375 units of Liquidia Corp stock worth over $26,430,427 and over the last 10 years Viii sold LQDA stock worth over $12,885,261.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Viii Vii LQDA stock SEC Form 4 insiders trading

Viii has made over 51 trades of the Liquidia Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently Viii sold 11,375 units of LQDA stock worth $46,524 on 26 July 2021.

The largest trade Viii's ever made was buying 727,273 units of Liquidia Corp stock on 30 July 2018 worth over $8,000,003. On average, Viii trades about 42,239 units every 41 days since 2014. As of 26 July 2021 Viii still owns at least 2,603,983 units of Liquidia Corp stock.

You can see the complete history of Viii Vii stock trades at the bottom of the page.

What's Viii Vii's mailing address?

Viii's mailing address filed with the SEC is 285 RIVERSIDE AVENUE,285 RIVERSIDE AVENUE,, SUITE 250SUITE 250, WESTPORTWESTPORT, CTCT, 0688006880.

Insiders trading at Liquidia Corp

Over the last 6 years, insiders at Liquidia Corp have traded over $16,750,945 worth of Liquidia Corp stock and bought 12,456,625 units worth $100,694,400 . The most active insiders traders include Forest Baskett, Scott D Sandell et Peter J Barris. On average, Liquidia Corp executives and independent directors trade stock every 18 days with the average trade being worth of $1,467,274. The most recent stock trade was executed by Russell Schundler on 30 August 2024, trading 2,344 units of LQDA stock currently worth $23,792.

What does Liquidia Corp do?

liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.

Complete history of Viii Vii stock trades at Spark Networks SE, Cardlytics Inc et Liquidia Corp

Liquidia Corp executives and stock owners

Liquidia Corp executives and other stock owners filed with the SEC include:

• Neal Fowler,
  Chief Executive Officer and Director
• Robert Lippe,
  Chief Operations Officer
• Robert A. Lippe,
  Chief Operations Officer
• Dr. Tushar Shah M.D.,
  Sr. VP of Product Devel. & Chief Medical Officer
• Damian deGoa,
  CEO & Director
• Stephen Bloch,
  Independent Chairman of the board
• Ralph Snyderman,
  Independent Director
• Raman Singh,
  Independent Director
• Seth Rudnick,
  Independent Director
• Arthur Kirsch,
  Independent Director
• Katherine Rielly-Gauvin,
  Independent Director
• Joanna Horobin,
  Independent Director
• Dr. Roger A. Jeffs Ph.D.,
  CEO & Director
• Tushar Shah,
  Chief Medical Officer
• Jeri Thomas,
  Senior Vice President - Commercial
• Robert Roscigno,
  Senior Vice President - Product Development
• Benjamin Maynor,
  Senior Vice President - Research & Development
• Steven Bariahtaris,
  Interim Chief Financial Officer
• Celia Reyes-Hoke,
  VP of People & Culture
• Scott Moomaw,
  Sr. VP of Commercial
• Jason Adair,
  Sr. VP of Corp. Devel. & Strategy
• Russell Schundler,
  Gen. Counsel & Corp. Sec.
• Jennifer Almond,
  Director of Investor Relations & Corp. Communications
• Michael Kaseta,
  Chief Financial Officer
• Dr. Ginger Denison,
  Co-Founder
• William R. Kenan Jr.,
  Co-Founder
• Partners Lpjohnson David Ed...,
  
• Ventures, Llceshelman Fredr...,
  
• Damian De Goa,
  Director
• Kevin K Gordon,
  President and CFO
• Edward T Mathers,
  Director
• Timothy Albury,
  SVP, Chief Accounting Officer
• Lt Ltd Zahir Fares Xeraya,
  
• Peter J Barris,
  10% owner
• M James Barrett,
  10% owner
• & Melinda Gates Foundation ...,
  
• Group Iv, Llc Wakefield,
  10% owner
• Group Iii, Llc Wakefield,
  10% owner
• Venture Investments Ltd Mor...,
  10% owner
• Product Development, Llc Wi...,
  
• Viii Lp Canaan Partners Vii...,
  
• Group Pte Ltdvorobyev Maxim...,
  
• Capital Spc Ltdal Wealth Pa...,
  
• Scott D Sandell,
  10% owner
• Patrick J Kerins,
  10% owner
• Forest Baskett,
  10% owner
• East Ltd Bathurst Enterpris...,
  
• Plc Gsk,
  
• Enterprise Associates 12, L...,
  
• Of North Carolina At Chapel...,
  10% owner
• Capital Ii, Lp Sovereign's,
  10% owner
• Revelation Healthcare Fund ...,
  
• Family Credit Llc Series D ...,
  
• Mutual Holdings, Inc. Medical,
  10% owner
• Arthur Ma.M. Pappas Life Sc...,
  
• Ltd Bathurst Enterprises Lt...,
  
• David Edward Johnson,
  Director
• Shawn Glidden,
  VP,Legal Affairs and Secretary
• Richard D Katz,
  Chief Financial Officer
• David Edward Caligan Partne...,
  
• Michael Kaseta,
  CFO and COO
• Florina Krawchick,
  SVP, Human Resources
• Rajeev Saggar,
  Chief Medical Officer
• Scott Moomaw,
  Chief Commercial Officer
• Roger Jeffs,
  Chief Executive Officer
• Russell Schundler,
  General Counsel
• Paul B Manning,
  Director
• Jason Adair,
  Chief Business Officer